Comparison of the Efficacy and Safety of Recombinant Human Erythropoietin Administered at Different Frequencies in Patients with Maintenance Hemodialysis
Objective:To explore and compare the efficacy and safety of recombinant human erythropoietin administered at different frequencies in patients with maintenance hemodialysis.Methods:A total of 72 patients on maintenance hemodialysis admitted to our hospital from May 2021 to October 2023 were selected,and were randomly divided into a control group and an observation group,with 36 cases in each group.Recombinant human erythropoietin was used as adjuvant therapy in both groups.The control group received multiple weekly doses,while the observation group received a single weekly dose.Iron metabolism[serum ferritin(SF),hemoglobin level(Hb),transferrin saturation(TSAT)],efficacy and adverse reactions were compared between the two groups.Results:Before treatment,there was no significant difference in the levels of SF,Hb and TSAT between the two groups(P>0.05).At 4 weeks and 12 weeks of treatment,the levels of SF,Hb and TSAT in the two groups gradually increased and were higher than those before treatment.The levels in the observation group were higher than those in the control group,with a significant difference(P<0.05);The effective rate of the observation group was higher than that of the control group(P<0.05),and there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Recombinant human erythropoietin administered as a single weekly dose can improve the anemia of patients,enhance the efficacy and ensure the safety of treatment.
recombinant human erythropoietindifferent frequenciesmaintenance hemodialysistherapeutic effectliver functionadverse reactions
NETL
NSTL
万方数据
